<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762862</url>
  </required_header>
  <id_info>
    <org_study_id>21LGTS01</org_study_id>
    <nct_id>NCT04762862</nct_id>
  </id_info>
  <brief_title>QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy</brief_title>
  <acronym>QUANTACT</acronym>
  <official_title>QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Precision medicine and targeted therapies have played a crucial role over the past ten years&#xD;
      in the personalized care of cancer patients. In this retrospective and observational study,&#xD;
      we focused on patients for which no standard or curative treatment was available and for&#xD;
      which the management was discussed in a Molecular Tumor Board (MTB).&#xD;
&#xD;
      The role of the MTB is to decide the most appropriate therapeutic options for patients&#xD;
      according to the potential identification of molecular targets.&#xD;
&#xD;
      Among the analyses carried out, we focused on a quantitative genome-wide analysis: the&#xD;
      CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array).&#xD;
      The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of&#xD;
      targeted molecular alterations.&#xD;
&#xD;
      &quot;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of targeted molecular alterations</measure>
    <time_frame>at day 0</time_frame>
    <description>Number of targeted molecular alterations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients eligible for targeted therapy (clinical trials or &quot;off-label&quot; drug)</measure>
    <time_frame>at day 0</time_frame>
    <description>Number of patients eligible for targeted therapy (clinical trials or &quot;off-label&quot; drug)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Solid Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients for which no standard or curative treatment was available and for which the&#xD;
        personalized management was discussed in a Molecular Tumor Board.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor malignancy that is advanced or&#xD;
             metastatic ;&#xD;
&#xD;
          -  no standard or curative treatment available;&#xD;
&#xD;
          -  non-opposition of the patient collected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple cancer patient;&#xD;
&#xD;
          -  ECOG Scale of Performance Status (PS) â‰¥2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

